Research programme: CCR5/CXCR4 antagonists - Progenics
Latest Information Update: 19 Jun 2020
Price :
$50 *
At a glance
- Originator Progenics Pharmaceuticals; Roche
- Developer Progenics Pharmaceuticals
- Class Small molecules
- Mechanism of Action CCR5 receptor antagonists; CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 21 Aug 2007 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
- 26 Aug 2005 No development reported - Preclinical for HIV infections treatment in USA (unspecified route)